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The electrophysiologic effects and response to pro-
grammed ventricular stimulation of intravenous pro-
pafenone, an experimental antiarrhythmic agent, were
studied in a group of 14 patients with both clinical and
induced sustained ventricular tachycardia. Twelveof the
14 patients had not responded to conventional anti-
arrhythmic drug therapy. Propafenone had no signifi-
cant effect on sinus cycle length (836 ± 170 ms before
and 750 ± 124 ms after propafenone), P wave duration
(108 ± 24 ms before and 106 ± 23 msafter propafenone)
or PR interval (181 ± 45 ms before and 194 ± 53 ms
after propafenone). QRS duration and ventricular ef-
fective refractory periods increased significantly(109 ±
20 to 130 ± 21 ms and 235 ± 24 to 256 ± 19 ms,
respectively).
Ventricular tachycardia remained inducible or oc-
curred spontaneously in 13 of 14 patients after propa-
Propafenone hydrochloride is an experimental anti-
arrhythmic agent that had been used for treating supraven-
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fenone administration. Neither mode of initiation nor
mode of termination of ventricular tachycardia was pre-
dictably altered. Additional forms of ventricular tachy-
cardia were seen in six patients. Cycle length of ven-
tricular tachycardia was 303 ± 73 ms before and 346
± 143 ms after propafenone (p = NS).
In conclusion, intravenous propafenone does not sig-
nificantly affect sinus rate, intraatrial conduction or
atrioventricular conduction. Ventricular refractoriness
and intraventricular conductionare prolonged. The mode
of initiation, mode of termination and ventricular tachy-
cardia cycle length are not predictably altered, but ven-
tricular tachycardia occasionally occurs spontaneously
after propafenone. Intravenous propafenone rarely pre-
vents induction of ventricular tachycardia in patients
with sustained ventricular tachycardia refractory to con-
ventional antiarrhythmic agents.
tricular and ventricular tachyarrhythmias (l,2). Its anti-
arrhythmic activity is mediated mainly through its effect on
the fast inward sodium current , although it possesses slow
channel blocking and beta-receptor blocking properties (3-6).
Most of the clinical experience with this drug in ven-
tricular arrhythmias has been in treating complex ventricular
arrhythmia and nonsustained ventricular tachycardia (7-10).
The efficacy of the drug in sustained ventricular arrhythmias
as assessed by programmed electrical stimulation remains
unknown. We, therefore , studied the effects of intravenous
propafenone on: I) inducibility, mode of initiation and mode
of termination, cycle length and morphology of ventricular
tachycardia , and 2) intracardiac conduction and ventricular
effective refractory periods .
Methods
Study patients. Fourteen patients with spontaneous sus-
tained ventricular tachycardia induced by programmed ven-
tricular stimulation underwent electrophysiologic testing.
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Cardiac diagnoses were: coronary artery disease (II pa-
tients), dilated cardiomyopathy (I patient), restrictive car-
diomyopathy (I patient) and aortic stenosis status after repair
of congenital supravalvular aortic stenosis (I patient). The
mean age was 55 years; there were 12 men and 2 women.
The clinical presentation was recurrent sustained ventricular
tachycardia in eight patients, cardiac arrest in two patients,
syncope in two patients, palpitation in one patient and no
symptoms in one patient. In 12 of the 14 patients, ventricular
tachycardia was induced with one or more conventional
antiarrhy thmic agents during electrophysiologic study.
Study protocol. All patients had at least two baseline
inductions of ventricular tachycardia when taken off all med-
ication. Propafenone was given as follows: Patients 1, 2
and 3 rec eived intravenous propafenone (1 mg/kg) and were
retested within 30 minutes of the bolus injection. Seven
patients (Patients 4 to 10) received 2 mg/kg intravenously
and four patients (Patients 11 to 14) received 2 mg/kg in-
travenously followed by a constant infusion of 2 mg/min .
The first 10 patients received propafenone in a double-blind
crossover fashion, with both propafenone and placebo ad-
ministered during the same electrophysiologic study. The
dosage was increased from 1 to 2 mg/kg intravenously and
the constant infusion was added when none of the first 10
patients had a salutary response to the drug. Our stimulation
protocol for induction of ventricular tachycardia has been
reported previously in detail (II) and was the same before
and after the administration of propafenone.
Termination of ventricular tachycardia both before and
after propafenone was accomplished as reported previously
(12). Cardioversion was performed if ventricular tachy-
cardia was accelerated by pacing techniques or was poorly
tolerated. Stimuli were rectangular pulse widths I ms in
duration delivered at twice diastolic threshold. Ventricular
stimulation was performed with a specially designed pro-
grammable stimulator (Bloom Associates, Ltd.).
Sinus cycle length, P wave and QRS duration and PR
intervals were measured for three cardiac cycles at paper
speeds <of 100 to 200 mm/s. P waves and QRS duration
were measured from the earliest onset and latest offset on
the three simultaneous surface electrocardiographic leads (I,
aVF and V I) ' PR intervals were measured from the earliest
onset of (he P wave to the earliest onset of the QRS complex
in any simultaneous lead. Statistical analysis was performed
using the Student's t test for paired data as appropriate.
Results
Effect of propafenone on conduction times. Sinus cycle
length , P wave duration , PR interval and QRS duration were
assessed in the control state and after the administration of
propafenone (Fig. 1). Propafenone had no significant effect
on sinus cycle length (836 ± 170 ms before and 750 ±
124 ms after propafenone), P wave duration (l08 ± 24 ms
before and 106 ± 23 ms after propafenone) or PR interval
(181 ± 45 ms before and 194 ± 53 ms after propafenone).
QRS duration increased significantly from 109 ± 20 to 130
± 21 ms after the administration of propafenone (p <
0.001).
Effect of propafenone administration on ventricular
effective refractory period. Ventricular effective refrac-
tory periods were measured from the right ventricular apex
before and after propafenone in II patients. The mean re-
fractory period was 235 ± 24 ms before and 256 ± 19 ms
after propafenone (p < 0.005) .
Effect of propafenone on inducibility and mode of
initiation of sustained ventricular tachycardia. Thirteen
of 14 patients had sustained ventricular tachycardia that
either remained inducible or occurred spontaneously after
propafenone. Ventricular tachycardia was induced with the
same number of extrastimuli in nine patients, more extra-
stimuli were required in two patients, two patients had sus-
tained ventricular tachycardia spontaneously after propa-
fenone and one patient had no ventricular tachycardia in-
duced . Additional forms of ventricular tachycardia were
seen in six patients . Propafenone tended to prolong the cycle
length of ventricular tachycardia (303 ± 73 ms before and
346 ± 143 ms after propafenone), but this did not reach
statistical significance (p = 0.15) (Fig. 2). When this anal-
ysis was limited to ventricular tachycardia that was the same
morphologically before and after propafenone (10 patients),
ventricular tachycardia cycle length increased from 302 ±
66 ms before to 368 ± 160 ms after propafenone (p =
0.051) .
Mode of termination of ventricular tachycardia after
administration ofpropafenone. In four patients, the mode
of termination of ventricular tachycardia was the same be-
fore and after propafenone (rapid pacing in three patients
and cardioversion in one patient) . In four of the patients,
after propafenone the tachycardia was easier to terminate
(one patient), stopped spontaneously (two patients) or one
episode of ventricular tachycardia stopped spontaneously
and a second episode was easier to terminate (one patient) .
In the two patients in whom ventricular tachycardia was
more easily terminated after propafenone, rapid ventricular
pacing was required for termination in the control state and
a single extrastimulus terminated ventricular tachycardia after
propafenone.
In five patients, ventricular tachycardia was more difficult
to terminate after propafenone. Four of these patients re-
quired cardioversion after propafenone, whereas rapid ven-
tricular pacing had terminated ventricular tachycardia in the
basal state. The reasons for cardioversion were: acceleration
of ventricular tachycardia after rapid ventricular pacing that
did not accelerate ventricular tachycardia in the basal state
(two patients); induction of a more rapid, poorly tolerated
ventricular tachycardia (one patient) and incessant ventric-
ular tachycardia of multiple configurations after propafenone
380 DOHERTY ET AL.
PROPAFENONE HYDROCHLORIDE
lACC Vol. 4. No, 2
August J984:378- 81
p
p=ns
PLOOf
C
T
600
1200
100 .~.Sinus PwaveCycle msLength
•
ms 800
• ~
5
Figure I. Electrophysiologic effects of intravenous
propafenone on sinus cycle length, P wave duration,
PR .interval and QRS duration in the control state
(C) and after propafenone (P) .
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(one patient). One patient continued to have ventricular
tachycardia that ultimately terminated spontaneously some
time after the electrophysiologic study .
There was no relation between the ease of termination
of ventricular tachycardia after administration of propafen-
Figure 2. Ventricular tachycardia (VT) cycle length during con-
trol state (C) and after propafenone (P).
one compared with baseline and change in cycle length of
ventricular tachycardia. In the four patients whose tachy-
cardia was easier to terminate after propafenone, ventricular
tachycardia cycle length increased from 325 ± 90 ms before
to 336 ± 53 ms after propafenone (p = 0.42). In the five
patients whose tachycardia was more difficult to terminate,
tachycardia cycle length changed from 313 ± 67 ms before
to 399 ± 213 ms after propafenone (p = 0.15).
pans Discussion
Pharmacologic properties. Propafenone is an experi-
mental antiarrhythmic agent with unique pharmacologic
properties . It is known to cause a concentration-dependent
decrease in the fast inward sodium current (4). In the same
model, propafenone has demonstrated frequency-dependent
characteristics (3). Propafenone also has modest effects on
the slow inward current of calcium (6), although its calcium
antagonistic properties have generally been thought to bepC
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weak (5). Propafenone has also been shown to have modest
beta-receptor blocking properties with predominantly a beta,
affinity (5) and to abolish arrhythmias due to calcium chlo-
ride , dig italis intoxication or coronary ligation (13).
Comparison with previous studies. Several studies (7-9)
have shown oral propafenone to be effective in suppressing
complex ventricular arrhythmias. In one series of 13 patients
treated with oral propafenone for complex ventricular ec-
topic act ivity (14), the patients exhibited greater than 90%
suppres sion of isolated ventricular premature depolariza-
tions. As in our study, no significant change in heart rate
was observed after the administration of propafenone. The
PR interval, however, increased by 20% as did the QRS
duration . Meyer-Estorf et al. (15) also found that propa-
fcnone prolonged atrioventricular conduction and used PR
prolongation as a clinical index of plasma concentration.
We found no significant increase in the PR interval in our
patient s. The lack of increase in atrioventricular conduction
may be due to the mode of administration (that is, oral
comp ared with intravenous propafenone) or may be due to
the beta-adrenergic blocking effec ts of propafenone that may
only be evident at higher dose levels. The increase in QRS
duration we observed is in agreement with the results of
Connolly et al. (14). We found a significant increase in the
duration of the ventricular effective refractory period in
accord with that observed in a previous report (16).
Present study. Sustained ventricular tachycardia re-
mained inducible in 13 of 14 patients in our study. The
cycle length of ventricular tachycardia in the control state
and after the administration of propafenone did not differ
statistica lly, probably because of the wide range in cycle
lengths (,1' ventricular tachycardi a both before and after pro-
pafenone However, in some patients the degree of slowing
was dramatic. As with other antiarrhythmic agents, admin-
istration of propafenone resulted in ventricular tachycardia
whose morphologic feature s differed from those induced in
the basal state. It is unlikely that the low response rate in
this group was due to inadequate dosing, because we ob-
served substantial effects on intraventricular conduction and
ventricular refractoriness. It is , of course, impossible to
assess the effects of active metabolites with acute intrave-
nous dosing , although no such metabolites have been de-
scribed for propafenone. The spontaneous emergence of
sustained ventricular tachycardi a in two patients who had
been clinically free of arrhythmias for some time before the
study raises the possibility that propafenone may facilit ate
arrhyth mias in some patient s.
Conclusion. Intravenous propafenone caused no change
in intraatrial or atrioventr icular conduction, but prolonged
intravent ricular conduction and ventricular refractoriness.
In this regard, it behaved like a type lA antiarrhythmic
agent. Ventricular tachycardia remained inducible in 13 of
14 patient s. The mode of initiation , mode of termination
and cycle length of ventricul ar tachycardia were not pre-
dictably altered . Propafenone appea rs to have a limited role
in the treatment of recurrent sustained ventricular tachy-
cardia refractory to conventional agents as assessed by pro-
grammed ventricular stimulation.
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